methyl 4-chloro-1-naphthoate | 16726-68-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: methyl 4-chloro-1-naphthoate
• 英文别名: 4-Chlor-1-naphthalinsaeuremethylester；1-Naphthalenecarboxylic acid, 4-chloro-, methyl ester；methyl 4-chloronaphthalene-1-carboxylate
• CAS: 16726-68-4
• 化学式: C₁₂H₉ClO₂
• 分子量: 220.655
• InChiKey: HHBZFTGXGDEYDI-UHFFFAOYSA-N

物化性质

• 沸点：
  331.8±15.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 4-chloro-1-naphthoate 在 氯化亚砜 、 potassium hydroxide 作用下， 以 水 为溶剂， 反应 14.0h， 生成 4-chloro-1-naphthoyl chloride
  参考文献：
  名称：

  Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: Steric and electronic effects of 4- and 8-halogenated naphthoyl substituents

  摘要：

  To develop SAR at both the cannabinoid CB1 and CB2 receptors for 3-(1-naphthoyl)indoles bearing moderately electron withdrawing substituents at C-4 of the naphthoyl moiety, 1-propyl and 1-pentyl-3-(4-fluoro, chloro, bromo and iodo-1-naphthoyl) derivatives were prepared. To study the steric and electronic effects of substituents at the 8-position of the naphthoyl group, the 3-(4-chloro, bromo and iodo-1-naphthoyl) indoles were also synthesized. The affinities of both groups of compounds for the CB1 and CB2 receptors were determined and several of them were evaluated in vivo in the mouse. The effects of these substituents on receptor affinities and in vivo activity are discussed and structure-activity relationships are presented. Although many of these compounds are selective for the CB2 receptor, only three JWH-423, 1-propyl-3-(4-iodo-1-naphthoyl)indole, JWH-422, 2-methyl-1-propyl-3-(4-iodo-1-naphthoyl) indole, the 2-methyl analog of JWH-423 and JWH-417, 1-pentyl-3-(8-iodo-1-naphthoyl)indole, possess the desirable combination of low CB1 affinity and good CB2 affinity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.01.038
• 作为产物：
  描述：

  甲醇 、 4-Amino-naphthalene-1-carboxylic acid hydrochloride 在 盐酸 、 sodium nitrite 、 copper(l) chloride 、 水 作用下， 以 水 为溶剂， 反应 4.5h， 以13%的产率得到methyl 4-chloro-1-naphthoate
  参考文献：
  名称：

  EP1362846

  摘要：

  公开号：

文献信息

• Synthesis and Biological Effects of Novel 2-Amino-3-naphthoylthiophenes as Allosteric Enhancers of the A₁ Adenosine Receptor
  作者：Pier Giovanni Baraldi、Romeo Romagnoli、Maria Giovanna Pavani、Maria del Carmen Nuñez、Mojgan Aghazadeh Tabrizi、John C. Shryock、Edward Leung、Allan R. Moorman、Canan Uluoglu、Valeria Iannotta、Stefania Merighi、Pier Andrea Borea

  DOI：10.1021/jm0210212

  日期：2003.2.1

  cycloalkylthiophenes, tetrahydrobenzo[b]thiophene derivatives appeared to be more potent than the dihydrocyclopentadien[b]thiophene counterparts. Some of the most potent compounds were tested at a concentration of 10 microM for their affinity as competitors to the antagonist binding site of CHO cells expressing hA(1), hA(2A), and hA(3) adenosine receptors. None inhibited binding at the hA(2A)AR, but most

  当前的研究描述了一系列新型的2-氨基-3-萘噻吩并在噻吩的4-位和5-位以及萘环上有可变的修饰。以多种方式测量了变构增强子的活性：（1）在表达克隆的人A（C）的中国仓鼠卵巢（CHO）细胞中，在A（1）-腺苷激动剂（CPA）存在的情况下评估对福司柯林刺激的cAMP积累的影响。 1）-腺苷受体（hA（1）AR）; （2）这些化合物取代[（3）H] DPCPX，[（3）H] ZM 241385和[（3）H] MRE 3008F20与表达hA（ 1），hA（2A）和hA（3）腺苷受体；（3）对[（3）H] CCPA与表达hA（1）AR的CHO细胞膜结合的影响，含有天然腺苷A（1）受体的大鼠大脑和人类皮质膜制剂；（4）[（3）H] CCPA从CHO-hA1膜解离的动力学。药理分析比较了各种活性与参考化合物PD 81,723（化合物1）的活性。在CHO：hA（1）分析中，几种化合物似乎比PD 81,7
• Synthesis and Pharmacological Activity of Triazolo[1,5-<i>a</i>]triazine Derivatives Inhibiting Eosinophilia
  作者：Fumihiko Akahoshi、Shinji Takeda、Takehiro Okada、Masahiko Kajii、Hiroko Nishimura、Masanori Sugiura、Yoshihisa Inoue、Chikara Fukaya、Youichiro Naito、Takashi Imagawa、Norifumi Nakamura

  DOI：10.1021/jm970759u

  日期：1998.7.1

  )thiocarbonyl]-1H-1,2, 4-triazole. In the triazolo[1,5-a]triazine series, 2-(4-chlorophenyl)-6-methyl-1,2,4-triazolo[1,5-a]-1,3, 5-triazine-7(6H)-thione (3h) was highly potent, and when given orally it had an ID50 value of 0.3 mg/kg, which is comparable to that of GCC-AP0341. The fact that the structure-activity relationship of these two series was quite similar suggests that a common substructure

  在继续我们先前关于嗜酸性粒细胞增多抑制剂的工作时，我们合成了另外一系列抑制剂，包括5-氨基-1-[[（甲基氨基）硫代羰基] -1H-1,2,4-三唑衍生物和一系列新开发的抑制剂。 1,2,4-三唑并[1,5-a] -1,3,5-三嗪衍生物。我们评估了它们对气道嗜酸性粒细胞模型的抑制活性，该模型是通过静脉内（iv）注射Sephadex颗粒诱导的。在三唑环的3位带有多个取代基的1,2,4-三唑系列中，例如2-呋喃基，吡啶基和苯氧基，没有一种衍生物具有与先前报道的化合物GCC-AP0341相当的活性，即5-氨基-3-（4-氯苯基）-1-[（甲基氨基）硫代羰基] -1H-1,2，4-三唑。在三唑并[1,5-a]三嗪系列中，2-（4-氯苯基）-6-甲基-1,2,4-三唑并[1,5-a] -1,3，5-三嗪-7（6H）-硫酮（3h）具有很高的效力，口服时ID50值为0.3 mg / kg，与GCC-A
• Aminoethanol derivatives
  申请人：——

  公开号：US20040127574A1

  公开（公告）日：2004-07-01

  The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula 1 wherein Ar 1 is an aromatic ring group optionally having substituents, Ar 2 is an aromatic ring group having substituents, OR″ is an optionally protected hydroxyl group, R is an acyl group, R′ is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.

  本发明提供了一种具有胆固醇酯转移蛋白抑制作用的药物剂，可用作降低血脂等方面的药物。本发明涉及一种由式1表示的化合物，其中Ar1是一个带有取代基的芳香环基团，Ar2是一个带有取代基的芳香环基团，OR″是一个可选保护的羟基，R是一个酰基，R′是一个氢原子或一个可选带有取代基的碳氢基团，或其盐，以及含有式(I)的化合物或其盐或前药的药物组合物。
• Triazole derivative and pharmaceutical use thereof
  申请人：The Green Cross Corporation

  公开号：US05750545A1

  公开（公告）日：1998-05-12

  An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) ##STR1## or the following formula (III) ##STR2## wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all, have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action. They are low toxic and persistent in action. They are particularly effective in the treatment of accumulation and activation of eosinophil and lymphocytes, inflammatory respiratory tract diseases, eosinophil-related diseases such as eosinophilia, and immune-related diseases.

  一种用于预防和治疗免疫相关疾病的药剂，特别是免疫抑制剂，一种用于预防和治疗过敏疾病的药剂，一种用于预防和治疗嗜酸性粒细胞相关疾病和嗜酸性粒细胞抑制剂，包括以下式（I）的一系列三唑衍生物作为活性成分：##STR1## 或以下式（III）：##STR2## 其中每个符号如规范中所定义，或其药学上可接受的盐。一种新的单环或双环三唑衍生物。本发明的嗜酸性粒细胞抑制剂和淋巴细胞激活抑制剂，以及预防和治疗免疫相关疾病，特别是免疫抑制剂，预防和治疗过敏疾病，预防和治疗嗜酸性粒细胞相关疾病，嗜酸性粒细胞抑制剂和本发明的新型三唑衍生物，都具有优越的嗜酸性粒细胞抑制作用和淋巴细胞激活抑制作用。它们毒性低且持久作用。它们在治疗嗜酸性粒细胞和淋巴细胞的积累和激活、炎症性呼吸道疾病、嗜酸性粒细胞相关疾病如嗜酸性粒细胞增多症以及免疫相关疾病方面特别有效。
• TRIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：THE GREEN CROSS CORPORATION

  公开号：EP0710654A1

  公开（公告）日：1996-05-08

  An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) or the following formula (III) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action. They are low toxic and persistent in action. They are particularly effective in the treatment of accumulation and activation of eosinophil and lymphocytes, inflammatory respiratory tract diseases, eosinophil-related diseases such as eosinophilia, and immune-related diseases.

  一种预防和治疗免疫相关疾病的制剂，特别是免疫抑制剂，一种预防和治疗过敏性疾病的制剂，一种预防和治疗嗜酸性粒细胞相关疾病的制剂和一种嗜酸性粒细胞增多抑制剂，其活性成分包括下式（I）的一系列三唑衍生物 或下式（III） 其中各符号如说明书中所定义，或其药学上可接受的盐。一种新型单环或双环三唑衍生物。本发明的预防和治疗免疫相关疾病的制剂，特别是免疫抑制剂、预防和治疗过敏性疾病的制剂、预防和治疗嗜酸性粒细胞相关疾病的制剂、嗜酸性粒细胞抑制剂和新型三唑衍生物都具有优异的嗜酸性粒细胞抑制作用和淋巴细胞活化抑制作用。它们毒性低，作用持久。它们对治疗嗜酸性粒细胞和淋巴细胞的积聚和活化、呼吸道炎症性疾病、嗜酸性粒细胞相关疾病（如嗜酸性粒细胞增多症）以及免疫相关疾病特别有效。